Drug Profile
Ferric carboxymaltose - Vifor
Alternative Names: Ferinject; Injectafer; Iron-dextri-maltose; Iroprem; Renegy; VIT-45; Z-213Latest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator Vifor
- Developer American Regent; Duke Clinical Research Institute; JW Pharmaceutical; Vifor; Zeria
- Class Antianaemics; Cardiovascular therapies; Heavy metals; Iron compounds
- Mechanism of Action Iron replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Iron deficiency anaemia
- Phase III Restless legs syndrome
Most Recent Events
- 29 Mar 2024 Vifor Pharma announces intention to launch ferric carboxymaltose for Iron deficiency anaemia in Canada in the second half of 2024
- 19 Mar 2024 Registered for Iron deficiency anaemia (In infants, In children, In adolescents, In adults, Treatment-experienced) in Canada (IV)
- 28 Aug 2023 Efficacy data from the phase III HEART-FID trial in Iron deficiency released by American Regent